ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2033

Novel Autoantibodies Identified in Seronegative Sjögren’s Disease Using Innovative Whole Peptidome Array Technology

Maxwell Parker, Zihao Zheng, Quinn Parker, Addie Vande Loo, Michael Newton, Miriam Shelef and Sara McCoy, University of Wisconsin, Madison, WI

Meeting: ACR Convergence 2022

Keywords: Autoantibody(ies), Diagnostic criteria, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Sjögren's Syndrome – Basic and Clinical Science Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: SjD disease (SjD) is typically diagnosed by the presence of an anti-SSA antibody or focal lymphocytic sialadenitis in salivary gland tissue. Among SjD patients who are anti-SSA antibody negative (SSA-), a salivary gland biopsy is required for diagnosis. Our objective was to identify novel autoantibodies as a non-invasive means to diagnose SSA- SjD.

Methods: Using sera from SSA- SjD (n=8) and age- sex-matched healthy controls (n=8), IgG binding to a high density whole human peptidome array was quantified. The highest bound peptides from the array, as defined by MixTwice method, were internally validated by ELISA using sera from the same subjects. Based on results from internal validation, 12 peptides were selected for ELISA external validation using sera from the following age-, sex-, and race-matched groups from the SICCA biorepository: SSA- SjD subjects (meet 2016 ACR/EULAR criteria for SjD; n=76), sicca controls (sicca with negative ANA, rheumatoid factor, SSA, and focus score < 1; n=75), and autoimmune controls (positive ANA (≥1:320), rheumatoid factor, or SSA, but fail to meet 2016 ACR/EULAR criteria for SjD; n=38). ELISA results were compared using parametric testing for sample sizes ≥15 and likelihood ratio chi-square for categorical variables. We performed adaptive shrinkage with Lasso regression to select peptides for a random forest model to predict SSA- SjD.

Results: IgG against a peptide from Q8NEN9 (PDZ domain-containing protein 8) was greater in SSA- SjD and sicca controls than autoimmune controls (p< 0.001 and 0.02, respectively; Figure 1). IgG against Q9NSI6 (Bromodomain and WD repeat-containing protein 1) and Q9H2G2 (STE-like serine/threonine-protein kinase) was higher in SSA- SjD than sicca controls among White/Hispanic subjects (p=0.02 and p=0.03, respectively; Figure 2). After defining positive cutoffs, Q9NSI6 and Q9H2G2 were positive more in SSA- SjD than sicca controls (16% vs. 0 [p=0.0002] and 20% vs. 5% [p=0.03], respectively) in White/Hispanic subjects. We also found IgG bound Q8NG31 (Kinetochore scaffold 1) less in SSA- SjD than sicca controls (60% vs. 89% positive, respectively; p=0.02). IgG from SjD and sicca control subjects binds a Q8NEN9 peptide more than autoimmune controls. We included eight peptides in our random forest model and achieved an area under the receiver operator curve of 0.97 to predict SSA- SjD among White/Hispanic subjects. Among Asian/African American subjects, IgG binding to peptides from Q9NSI6 and Q12756 (Kinesin-like protein KIF1A) differed between SSA- SjD, autoimmune, and sicca controls (Figure 3).

Conclusion: We present novel autoantibodies unique to SSA- SjD compared to autoimmune- and sicca-controls. These antibodies have good predictive value amongst Whites/Hispanic subjects for SjD. Future directions include performing further modeling in validation cohorts and discerning associations between autoantibodies and SjD characteristics.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: M. Parker, None; Z. Zheng, None; Q. Parker, None; A. Vande Loo, None; M. Newton, None; M. Shelef, None; S. McCoy, Novartis, Bristol-Myers Squibb(BMS).

To cite this abstract in AMA style:

Parker M, Zheng Z, Parker Q, Vande Loo A, Newton M, Shelef M, McCoy S. Novel Autoantibodies Identified in Seronegative Sjögren’s Disease Using Innovative Whole Peptidome Array Technology [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/novel-autoantibodies-identified-in-seronegative-sjogrens-disease-using-innovative-whole-peptidome-array-technology/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/novel-autoantibodies-identified-in-seronegative-sjogrens-disease-using-innovative-whole-peptidome-array-technology/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology